PCN149 TRANSFERABILITY OF PHARMACOECONOMIC EVALUATIONS: CASE STUDY OF TRASTUZUMAB FOR EARLY BREAST CANCER
Carswell C, McWilliams P, Lyseng-Williamson KA, Faulds D Adis, Auckland, New Zealand OBJECTIVES: Using a simple method we determined the potential transferability of a previous economic evaluation on the cost effectiveness of adjuvant trastuzumab therapy for the treatment of HER2/Neu-positive breast cancer in Canada (Skedgel et al, 2009 ) to five other countries (UK, US, Australia, Japan and Germany). METHODS: Based on data from a literature review, we firstly identified all possible transferability factors. From this we selected key transferability factors -those with values that differed across the countries or were factors that were shown to influence the cost-effectiveness ratio in sensitivity analysis in the Canadian reference study. We then considered the ease of transferability (ranging from very low to very high) for each of these potential factors from the Canadian study to the other countries. RESULTS: We identified seven potential key factors for transferability: cost discount rate, health outcomes discount rate, unit costs (particularly drug acquisition cost), resources used, treatment effectiveness, (including duration of benefit) and measures used to determine utility values. Overall, potential transferability was highest for the UK, where treatment practice is similar to that in Canada and data on unit costs, resource use and discount rates are readily available. Because the authors of the reference study did not report unit costs and resource use separately, however, transferability of the analysis was hindered. Transferability to Australia, Germany and the United States was of an intermediate level, while transferability to the Japanese setting was the lowest because treatment practice is likely to be different, and little cost of illness and utility data exist for that country. CONCLUSIONS: Several key factors need to be considered when evaluating whether a study is transferable to another setting. To enable the transferability of economic evaluations from one country to another, authors need to ensure that they report their economic data clearly and in sufficient detail. 
PCN150 DIRECT MEDICAL COSTS OF HEAD AND NECK CANCER IN THE UNITED STATES: AN ANALYSIS USING POOLED MEDICAL EXPENDITURE PANEL SURVEY (MEPS) DATA

OBJECTIVES:
Pooling annual data together from the Medical Expenditure Panel Survey (MEPS) is legitimate way to produce average annual estimates based on "person-years" for any condition. AHRQ state that over 100 cases are required in order to do this. The objective of this study is to look at the direct medical costs associated with head and neck cancer (HNC) using this data source. METHODS: MEPS data was pooled (2003) (2004) (2005) (2006) (2007) (2008) and analyzed for respondents with HNC (CCS codeϭ11). Two different approaches were used. Consolidated year files and condition files were pooled together to calculate estimates on use and expenditures for persons with HNC (condition approach). Yearly event files were used to pool condition-event files to establish an attributable fraction approach. Both approaches inflated expenditure data to 2008 USD. RESULTS: A total of 120 respondents were identified to have a diagnosis of HNC when data was pooled. The condition approach estimated that the national yearly expenditures of HNC is in the order of $16.47bn with mean spend of $14,573 (SEϮ$2,227) per case per year. The attributable fraction approach estimated that expenditures for all events associated with HNC are significantly less -$8.49bn with a mean of $4788 (SEϮ$1,057) per case per year. There were only 103 cases that had an event associated with the condition. Private payors accounted for most expenditure, though the proportion was slightly lower using the condition approach (46% vs. 56%). The analysis noted that attributable expenditures were driven by ambulatory visits where condition expenditures were driven by inpatient costs. CONCLUSIONS: MEPS is often used to estimate the direct medical costs of a condition. This analysis illustrates that for rare cases, such as HNC, that both approaches offer insight into characterizing a condition. Subsequently, a range for cost estimates can be determined using this data source.
PCN151 DESIGNING CASE REPORT FORMS FOR ECONOMIC EVALUATION ALONG SIDE CLINICAL TRIALS: A CASE-STUDY USING AN INTERACTIVE DATA ANALYSIS TOOL TO STREAMLINE DATA COLLECTION
Foley K Thomson Reuters, Cambridge, MA, USA OBJECTIVES: Determining which economic and health resource utilization data points to collect in clinical trials requires a balance between comprehensiveness and data collection burden. Cost and time constraints necessitate that only the most critical economic variables be collected. Our objective was to test the utility of a new tool for determining the most frequent types and timing of healthcare utilization among cancer patients in a quick and low cost manner. METHODS: We used an online interactive data analysis tool, MarketScan ® Treatment Pathways, to explore the most frequent adverse events (AE) and their related healthcare utilization patterns in a sample of non-small cell cancer patients (NSCLC). Patients with at least 2 ICD-9 codes for lung cancer on different days within 30 days of each other on non-rule out claims and no chemotherapies associated with small-cell lung cancer were included. The subset of patients with a diagnosis for metastatic cancer following their NSCLC diagnosis who received at least one oral or injectible chemotherapy treatment were analyzed. RESULTS: 5,243 patients with metastatic NSCLC were identified, of whom 2,006 received at least one oral or injectible treatment. 80% of experienced at least one AE serious enough to require healthcare intervention. The median and mean days to the first AE were 20 and 51.5 days from the time of the first treatment. The most common AEs were anemia (51.2%), gastrointestinal events (34.8%), fatigue (26.1%), and neutropenia (24.2%). Of those with anemia, 36% received epoetin or darbepoetin alpha and of those with neutropenia, 77% received pegfilgrastim or filgrastim. Additional patient clinical and treatment characteristics were described for the 30 days following each AE. Total analysis time for this project was under 3 hours. CONCLUSIONS: Treatment Pathways answered critical questions for the design of economic endpoint data collection for a new cancer trial in just a few hours. 
PCN153 A TRIAL FOR EVALUATING BREAST CANCER TUMOR MARKER USE IMPACT: A VALUE OF RESEARCH ANALYSIS
OBJECTIVES:
Clinical trials of oncology products often allow crossover of control patients to the treatment arm following disease progression. This can underestimate a product's overall survival (OS) and raises challenges for cost-effectiveness analyses compared. METHODS: A lifetime model compared the cost-effectiveness of a hypothetical pancreatic cancer therapy (CRG001) to gemcitabine. Gemcitabine survival data were derived from published studies. A hazard ratio of 0.55 was assumed for CRG001. CRG001 cost $2500 every 2 weeks for a maximum of 12 cycles and gemcitabine cost $200 every 1 week for a maximum of 24 cycles. Analyses were conducted: 1) 0%; 2) 50%; and 3) 85% crossover of gemcitabine patients to CRG001. Patient crossover occurred at the time of disease progression. Crossover patients received the CRG001 hazard ratio. Patients progressing in CRG001 were assumed to receive palliative care. A secondary analysis allowed 50% crossover but excluded second-line costs of CRG001. Costs and outcomes were discounted at 5%. RESULTS: The cost per QALY gained for CRG001 compared with current care was $81,352 with no cross-over, $69,292 with 50% crossover and 40,992 with 85% crossover. In the analysis where the cost of CRG001 was excluded in crossover patients, the ratio was $140,118. CONCLUSIONS: The first three analyses illustrate that CRG001 cost-effectiveness decreases with increasing cross-over of gemcitabine patients, if the costs of CRG001 for crossover patients are included. In our experience, however, reimbursement agencies often require a primary analysis that excludes secondline costs of the study drug for patients that cross-over. This analysis yields a high ratio that could lead to a negative reimbursement decision. In this case, where second-line CRG001 costs are excluded, adjustment of OS for crossover of gemcitabine patients is required. Overall, consideration must be given to the extent and potential impact of crossover when conducting cost-effectiveness analysis of new oncology products. 
PCN155 PATIENT BENEFIT-RISK PREFERENCES FOR ADVANCED RENAL CELL CARCINOMA TREATMENTS: RESULTS FROM A CONJOINT ANALYSIS STUDY
OBJECTIVES:
To quantify patients' benefit-risk preferences for benefits, toxicities, and serious adverse events of advanced RCC treatments. METHODS: Adult residents in the United States, with a self-reported diagnosis of RCC completed a web-enabled choice-format conjoint survey consisting of a series of 10 treatmentchoice questions, and a pair of hypothetical RCC medication profiles. Each profile had different attributes, i.e., efficacy [PFS] , tolerability [fatigue, stomach problems, mouth sores, hand-foot syndrome (HFS)], serious adverse events (lung damage and liver failure), and mode of administration. Treatment-choice questions were based on a predetermined experimental design with known statistical properties. Random-parameters logit was used to estimate relative preference weights for each attribute level, mean relative importance weights; and calculate risk tolerance for each adverse event for different improvements in PFS. RESULTS: A total of 272 respondents completed the survey. A 7-month improvement in PFS was the most important attribute. Remaining attributes were ranked in decreasing order of importance: eliminating severe fatigue (7.0; 95% CI: 4.6-9.4), eliminating severe stomach problems (7.0; 95% CI: 4.7-9.3), eliminating a 2% liver-failure risk (6.1; 95% CI: 4.0-8.2), eliminating severe mouth sores (5.7; 95% CI: 3.7-7.7), eliminating severe HFS (4.5; 95% CI: 2.7-6.4), eliminating a 2% lung-damage risk (4.1; 95% CI: 2.5-5.8), and switching from infusion once a week to 1 pill once a day (2.5; 95% CI: 1.4-3.6). To increase PFS by 1 month (baseline: 3 -4 months), patients accepted a maximum level of lung damage risk of 1.0% (95% CI: 0.8% -1.4%) and liver failure risk of 0.7% (95% CI: 0.4% -1.0%). A 7-month improvement in PFS was 2 times as important as eliminating severe HFS and a 2.0% risk of lung damage (P Ͻ 0.05). CONCLUSIONS: PFS was the most important outcome for RCC patients while severe fatigue and severe stomach problems were rated as the most troublesome toxicities.
PCN156 DEVELOPMENT AND VALIDATION OF A PATIENT-REPORTED QUESTIONNAIRE TO ASSESS THE QUALITY OF LIFE OUTCOMES OF INDIAN BREAST CANCER PATIENTS
Deshpande P, Chittkathopottamal AN, Bommareddy LS, Mallasamy S Manipal University, Manipal, Karnatak, India OBJECTIVES: To develop and validate a patient-reported questionnaire to assess the quality of life (QOL) outcomes of Indian breast cancer (BC) patients. METHODS: A 27-item questionnaire was developed by literature review, patient interviews (nϭ6) and expert opinions (nϭ15). The 24-item questionnaire was finalized. Total 11 domains were considered. The questionnaire was translated to local languages and then it was administered to BC patients (nϭ30) irrespective staging of cancer and type of therapy. The patients were interviewed and the responses were obtained. Internal consistency, acceptability, content validity, test-retest reliability of the questionnaire was determined and assessment the scores was performed statistically. RESULTS: A 24-item questionnaire was developed as per literature review, patient interviews and expert opinions. Cronbach's alpha value for the questionnaire was 0.93. Patients understood the questionnaire and found the items to be relevant indicating content validity. The statistical assessment of the scores was not showing the association between scores with age or stage of BC as sample size was less. CONCLUSIONS: The questionnaire shows good internal consistency, acceptability, content validity and test-retest reliability. It can be used to determine the QOL of BC patients. To our knowledge there is no other questionnaire to determine the QOL outcomes of Indian BC patients. For better results the instrument is needed to be used in larger population.
PCN157 TRANSLATION AND LINGUISTIC VALIDATION OF THE FACT-TH18 FOR USE WITH CANCER PATIENTS WITH THROMBOCYTOPENIA WORLDWIDE
Arnold B, Dhar J, Parks-Vernizzi E, Debb S FACITtrans, Elmhurst, IL, USA OBJECTIVES: Translation of patient reported outcomes (PRO) measures is an essential component of the research methodology required when preparing for multinational clinical trials. One such measure is the Functional Assessment of Cancer Therapy-Thrombocytopenia 18 questionnaire (FACT-Th18), which evaluates the quality of life (QOL) of cancer patients with thrombocytopenia. METHODS: This study set out to linguistically validate the FACT-Th18 scale for use in China, Greece, Hong Kong, Japan, India, Israel, Korea, Taiwan and Thailand. The combined sample consisted of 160 patients (81 males/79 females) diagnosed with thrombocytopenia. Patient mean age was 46 years, and at the time of administration, 146 patients were receiving treatment. The sample consisted of patients who speak Arabic, ChineseTraditional, Chinese-Simplified, Greek, Gujarati, Hebrew, Hindi, Japanese, Kannada, Korean, Malayalam, Marathi, Punjabi, Tamil, Telugu and Thai. The FACTTh18 was translated based on the established FACIT methodology. Patients completed the respective translated questionnaire corresponding to their primary language and then participated in a cognitive interview to determine if there were any problems with the translations or item content. Quantitative analyses were performed on the combined sample and participant comments were analyzed qualitatively in order to confirm the validity of the translations. RESULTS: During the translation process terms such as "petechiae", "pinpoint bruising" and "platelet transfusions" proved difficult to translate. The FACT-Th18 translations proved relevant to patients from a wide range of countries and were well understood. Very few items required adjustment to translations as a result of pilot-testing.
CONCLUSIONS:
The FACT-Th18 demonstrated linguistic validity across all 16 languages. The translations are considered acceptable for PRO assessment in international research and clinical trials.
